In clinical trials, the incidence of malignancies other than lymphoma and non-melanoma skin cancer per 100 patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the SIMPONI?? ARIA?? group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group.